Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitin-glucan is an insoluble fungal polysaccharide fiber and prebiotic nutraceutical derived from fungal cell walls, including *Aspergillus niger*. It is composed primarily of chitin and beta-glucan chains and has been investigated as an oral dietary supplement for cardiometabolic risk, abdominal obesity, oxidative stress and gut-microbiota modulation rather than as a conventional pharmaceutical. Reported human studies describe daily oral supplementation, including the branded preparation Kiotransine, with effects on postprandial glycemia, triglyceridemia, exhaled hydrogen, and gut microbiota composition; its proposed mechanism is non-receptor-mediated and centers on dietary fiber and prebiotic activity within the gastrointestinal tract, altering fermentation and metabolic responses rather than directly binding a defined molecular drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chitin-glucan.